For more than a decade, T cell-based immunotherapies have transformed cancer treatment, offering durable responses in diseases once considered untreatable. Yet despite their success in select cancers, most solid tumors remain resistant. One persistent barrier has been a surprisingly basic gap in knowledge: how the T cell receptor (TCR) itself is activated at the molecular level.
New research from The Rockefeller University now challenges long-standing assumptions about this foundational immune receptor. By visualizing the TCR in a membrane environment that closely mimics its natural setting, researchers uncovered an unexpected conformational switch that occurs at the very first step of T cell activation. The findings, published in Nature Communications, provide a new framework for understanding why some immunotherapies succeed while others fail—and how future therapies might be engineered more precisely.
Why T cell receptor mechanics matter
The TCR sits at the heart of nearly all T cell-based cancer therapies, including engineered T cell receptors, tumor-infiltrating lymphocytes, and chimeric antigen receptor (CAR) platforms. These approaches rely on the ability of T cells to recognize antigens presented by human leukocyte antigen (HLA) molecules and translate that recognition into intracellular signaling.
While the components of the TCR complex have been known for decades, the earliest steps of signal initiation—how antigen binding outside the cell triggers signaling inside—have remained unclear. This uncertainty has limited the rational design of therapies that depend on finely tuned receptor activation thresholds.
“The T cell receptor is really the basis of virtually all oncological immunotherapies, so it’s remarkable that we use the system but really have had no idea how it actually works,” said Holger Walz, PhD, senior author of the study and an expert in cryo-electron microscopy (cryo-EM).
Recreating the TCR’s native environment
A key reason this mechanism remained hidden lies in how the TCR has traditionally been studied. Nearly all prior structural studies relied on detergents to extract the receptor from the cell membrane. While effective for purification, detergents remove the lipid environment that stabilizes membrane proteins in living cells.
To overcome this limitation, the Rockefeller team embedded the full eight-protein TCR complex into nanodiscs—small, disc-shaped patches of lipid bilayer that closely resemble the natural T cell membrane. This allowed the researchers to image the receptor using cryo-EM while preserving critical membrane interactions.
Constructing this system was technically demanding. As first author Ryan Notti, MD, PhD, noted, assembling the entire receptor complex correctly within a nanodisc required precise control of membrane composition, thickness, and curvature. But the effort paid off.
A receptor that “springs open”
When visualized in its resting state, the TCR appeared compact and closed—contrary to decades of structural data suggesting that the receptor is constitutively open. Upon binding to an antigen-presenting HLA complex, however, the receptor underwent a dramatic conformational change, extending outward in what the authors describe as a “jack-in-the-box”-like motion.
This mechanical opening appears to be a crucial early step that enables downstream signaling inside the T cell. In detergent-based studies, the absence of the membrane likely allowed the receptor to adopt an artificially open conformation, obscuring this transition entirely.
“As far as anyone knew, the T cell receptor didn’t undergo any conformational changes when binding to antigens,” Notti said. “But we found that it does.”
Implications for immunotherapy design
The discovery has important implications for cancer immunotherapy. Many current therapies aim to increase T cell activation by amplifying signaling strength or blocking inhibitory pathways. However, without understanding how the receptor physically initiates signaling, such interventions can be blunt or unpredictable.
By revealing a discrete mechanical activation step, the study suggests new strategies for tuning T cell responses. For example, engineered receptors could potentially be designed to require less force to open, increasing sensitivity to weak tumor antigens. Conversely, raising the activation threshold could reduce off-target toxicity in settings such as adoptive cell therapy.
“Re-engineering the next generation of immunotherapies tops the charts in terms of unmet clinical needs,” Notti said, pointing to rare sarcomas and other tumors where current T cell therapies show limited benefit.
Beyond cancer: vaccines and immune precision
The findings may also inform vaccine development. Differences in how antigens engage and mechanically activate the TCR could influence the quality and durability of immune responses. Structural insights into these interactions could help guide the selection or engineering of antigens that more effectively prime T cells.
Walz emphasized that the work highlights the importance of studying immune receptors in environments that closely resemble living cells. “If we had just used a model lipid, we wouldn’t have seen this closed dormant state either,” he said.
At a time when immunotherapy development often focuses on clinical combinations and biomarkers, the study serves as a reminder that fundamental molecular insights can still reshape entire fields. By revisiting a core assumption about how T cells sense danger, the Rockefeller team has opened new possibilities for improving therapies that millions of patients already rely on.
